Voltar
Artigo Acesso aberto Produção Nacional
BIBTEX RIS

Rationale and design of the “Tocilizumab in patients with moderate to severe COVID-19: na open-label multicentre randomized controlled” trial (TOCIBRAS)

2020; Associação de Medicina Intensiva Brasileira; Volume: 32; Issue: 3 Linguagem: Inglês

10.5935/0103-507x.20200060

ISSN

1982-4335

Autores

Danielle Leão Cordeiro de Farias, João Antônio Gonçalves Garreta Prats, Alexandre Biasi Cavalcanti, Régis Goulart Rosa, Flávia Ribeiro Machado, Otávio Berwanger, Luciano César Pontes Azevedo, Renato D. Lópes, Álvaro Avezum, Letícia Kawano-Dourado, Lucas Petri Damiani, Salomón Soriano Ordinola Rojas, Cleyton Zanardo de Oliveira, Luís Eduardo Coelho Andrade, Alex Freire Sandes, Maria Carolina Tostes Pintão, Claudio Galvão de Castro Júnior, Phillip Scheinberg, Viviane Cordeiro Veiga,

Tópico(s)

Vitamin C and Antioxidants Research

Resumo

Pro-inflammatory markers play a significant role in the disease severity of patients with COVID-19. Thus, anti-inflammatory therapies are attractive agents for potentially combating the uncontrolled inflammatory cascade in these patients. We designed a trial testing tocilizumab versus standard of care intending to improve the outcomes by inhibiting interleukin-6, an important inflammatory mediator in COVID-19.

Referência(s)